research use only
Cat.No.S4715
| Related Targets | HDAC ATM/ATR DNA-PK WRN DNA/RNA Synthesis Topoisomerase PPAR Sirtuin Casein Kinase eIF |
|---|---|
| Other PARP Inhibitors | XAV-939 AZD5305 (Saruparib) Veliparib (ABT-888) PJ34 HCl AG-14361 Iniparib (BSI-201) G007-LK Pamiparib UPF 1069 A-966492 |
|
In vitro |
DMSO
: 24 mg/mL
(198.11 mM)
Ethanol : 24 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 121.14 | Formula | C7H7NO |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 55-21-0 | Download SDF | Storage of Stock Solutions |
|
|
| Targets/IC50/Ki |
PARP
(Cell-free assay) 3.3 μM
|
|---|---|
| In vitro |
Benzamide, an inhibitor of PARP is protective against excitatory amino acid-induced cell death in primary cultures of neurons derived from neonatal rat brain. In addition, this compound has more recently been shown to partially prevent the loss of dopaminergic cells and the increase in reactive gliosis caused by METH in vitro in fetal rat mesencephalic cells in culture. It prevents transformation in a cell cycle-specific manner, maximal prevention coinciding with early S phase, also characteristic of maximal susceptibility to transformation.
|
| In vivo |
PARP inhibitor benzamide is neuroprotective in C57Bl/6N mice against different types of neurotoxicities and without affecting body temperature. This compound treatment significantly decreases the iNOS expression and number of apoptotic neurons and thereby improves the neuronal survival and memory during GCI. Its administration (160 mg/kg i.p.) does not induce hypothermia and reaches the CNS in 30 min in the concentration range of 0.09-0.64 mM, at which, it shows neuroprotection.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01161836 | Completed | Advanced Solid Tumors |
Sanofi |
July 2010 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.